Mesenchymal Stromal Cells Mitigate Prolonged Cardiopulmonary Bypass-Induced Neuroinflammation
Open Access
- 6 November 2025
- journal article
- general interest
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (11)
Abstract
Objectives: Bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) can modulate CPB-induced systemic inflammation and inhibit microglial activation. The present study assessed whether BM-MSC treatment remains effective for extensive inflammatory reactions. Methods: Two-week-old piglets were randomized into control, CPB with deep hypothermic circulatory arrest (DHCA), CPB with BM-MSCs, CPB with DHCA plus 180 min extended perfusion, and extended CPB with BM-MSCs. Human BM-MSCs (1 × 107 cells/kg) were delivered via the CPB circuit during rewarming. We measured 9 porcine plasma cytokines. Brains were harvested for microglial immunohistochemistry and premotor cortex RNA-sequencing. Results: A total of 20 piglets were included (n = 4 per group). An extended CPB period increased the number of white matter microglia and plasma interferon-g (IFN-g) and TNF-a levels compared to standard CPB (P < .05). Notably, BM-MSCs normalized the extensive microglia expansion resulting from prolonged CPB (P < .001). In addition to reduced IFN-g and increased IL-10, BM-MSCs increased IL-1b and IL-8 levels, suggesting possible immunosuppressive reactions observed under inflammatory microenvironment. Gene ontology analyses in the premotor cortex post-CPB found involvement of NF-kB signalling. While there was a positive correlation between IFN-g and microglia expansion/activation, IL-10 levels were inversely correlated with the number of microglia. Consistent with immunosuppressive roles in the inflammatory environment, we found inverse correlations between IL-1b and IL-8 levels and CPB-induced microglial activation (P < .01). Conclusions: BM-MSC administration via CPB shows promise for reducing extensive inflammatory stress. Further investigation using this model will elucidate CPB-induced unique pathological events in the developing brain and mechanisms underlying the therapeutic actions of BM-MSC.Keywords
Funding Information
- National Institutes of Health (R01HL139712, R01HL146670, R21NS127051)
This publication has 30 references indexed in Scilit:
- Mesenchymal Stromal Cell Delivery Via Cardiopulmonary Bypass Provides Neuroprotection in a Juvenile Porcine ModelJACC: Basic To Translational Science, 2023
- Dose Effect of Mesenchymal Stromal Cell Delivery Through Cardiopulmonary BypassThe Annals of Thoracic Surgery, 2022
- Impact of Cardiopulmonary Bypass on Neurogenesis and Cortical MaturationAnnals of Neurology, 2021
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Strategies in adjusting for multiple comparisons: A primer for pediatric surgeonsJournal of Pediatric Surgery, 2020
- Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic PotentialTrends in Pharmacological Sciences, 2020
- Impact of Mesenchymal Stromal Cell Delivery Through Cardiopulmonary Bypass on Postnatal NeurogenesisThe Annals of Thoracic Surgery, 2020
- Prolonged White Matter Inflammation After Cardiopulmonary Bypass and Circulatory Arrest in a Juvenile Porcine ModelThe Annals of Thoracic Surgery, 2015
- Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion SystemCytotherapy, 2014
- Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1Stem Cells, 2012